Core Viewpoint - The announcement by the company regarding the overseas licensing option agreement with AbbVie Inc. for the investigational drug candidate SIM0500 highlights significant financial and developmental progress in their collaboration [1] Group 1: Financial Aspects - The company will receive an upfront payment from AbbVie, along with potential milestone payments that could total up to $1.055 billion [1] - Recently, the company has received an additional payment of $40 million from AbbVie, indicating positive progress in their clinical development collaboration for SIM0500 [1] Group 2: Product Development - SIM0500 is a humanized GPRC5D-BCMA-CD3 trispecific antibody developed using the company's proprietary T-cell engager multispecific antibody technology platform [1] - The molecule combines a low-affinity but highly targeted CD3 antibody with two tumor-associated antibodies: anti-G protein-coupled receptor C family member D (GPRC5D) and anti-B-cell maturation antigen (BCMA) [1] - SIM0500 demonstrates strong T-cell cytotoxic effects against multiple myeloma (MM) cells through various anti-tumor mechanisms [1]
先声药业(02096)：收到与AbbVie就SIM0500海外许可选择权协议的近期里程碑付款